Generic Name and Formulations:
Ursodiol 250mg; tabs.
Aptalis Pharmaceutical Technologies
Indications for URSO:
Primary biliary cirrhosis.
Take with food. 13–15mg/kg per day in 2–4 divided doses.
Complete biliary obstruction.
Variceal bleeding, hepatic encephalopathy, ascites, and/or need for an urgent liver transplant: give appropriate specific treatment. Monitor liver function and bilirubin monthly for 3 months after starting therapy, then every 6 months thereafter; consider discontinuing if levels increase significantly with history of stable liver function. Monitor and maintain bile flow. Pregnancy (Cat.B). Nursing mothers.
Reduced absorption with bile acid sequestrants (eg, cholestyramine, colestipol), and aluminum-containing antacids. Estrogens, oral contraceptives, clofibrate, other lipid-lowering drugs may reduce effectiveness of ursodiol by increasing hepatic cholesterol secretion.
Abdominal discomfort or pain, alopecia, diarrhea, nausea, pruritus, rash, leukopenia, elevated creatinine or blood glucose, thrombocytopenia.
Sign Up for Free e-newsletters
- 2016 Recommended Immunization Schedule for Adults: What's Changed?
- 2016 Childhood and Adolescent Immunization Schedule Released
- First Sexually-Transmitted Zika Virus Case Confirmed in Texas
- Spiriva Respimat Gains Indication and New Dosage Strength
- To Rx or Not to Rx: Interventions to Improve Antibiotic Prescribing for Uncomplicated Acute RTI
- CDC Guidelines on Preventing Sexual Transmission of Zika Virus Issued
- CDC Updates Interim Zika Virus Guidelines for Pregnant Women and Women of Reproductive Age
- Daklinza Use Expanded to Cover Treatment in More HCV Patients
- Researchers Call for an Alternative Tdap Immunization Strategy for Adolescents
- FDA Announces Large Action Plan in Effort to Reverse the Opioid Epidemic